ArticleJournal of neurovirology2004
A novel action of minocycline: inhibition of human immunodeficiency virus type 1 infection in microglia.
Article in Journal of neurovirology, 2004. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 37 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
37 citing papers in PubMed, 69 citations in OpenAlex.
- Randomized trial of minocycline in the treatment of HIV-associated cognitive impairment.Neurology · 2013Trial
- Minocycline inhibits somatic hyperalgesia induced by malocclusion through up-regulating spinal IL-10 expression in female rats.Naunyn-Schmiedeberg's archives of pharmacology · 2026Article
- HIV Cerebrospinal Fluid Escape: Interventions for the Management, Current Evidence and Future Perspectives.Tropical medicine and infectious disease · 2025Review
- Is the Neuroimmune System a Therapeutic Target for Opioid Use Disorder? A Systematic Review.Medical research archives · 2022Article
- Deficiency ofiScience · 2022Article
- Minocycline in Major Depressive Disorder: And overview with considerations on treatment-resistance and comparisons with other psychiatric disorders.Brain, behavior, & immunity - health · 2021Article
- Tetracycline and viruses: a possible treatment for COVID-19?Archives of virology · 2021Review
- Computational insights into tetracyclines as inhibitors against SARS-CoV-2 MLife sciences · 2020Article
- Altered behavior in mice overexpressing soluble ST2.Molecular brain · 2020Article
- Oral disease-modifying antirheumatic drugs and immunosuppressants with antiviral potential, including SARS-CoV-2 infection: a review.Therapeutic advances in musculoskeletal disease · 2020Article
- Scaling Synapses in the Presence of HIV.Neurochemical research · 2019Review
- Antiretroviral Drugs Alter the Content of Extracellular Vesicles from HIV-1-Infected Cells.Scientific reports · 2018Article
- The Role of Exosomal VP40 in Ebola Virus Disease.DNA and cell biology · 2017Review
- Lipopolysaccharide-Induced Apoptosis of Astrocytes: Therapeutic Intervention by Minocycline.Cellular and molecular neurobiology · 2016Article
- Minocycline attenuates HIV-1 infection and suppresses chronic immune activation in humanized NOD/LtsZ-scidIL-2Rγ(null) mice.Immunology · 2014Article
- Article
- Article
- Minocycline: far beyond an antibiotic.British journal of pharmacology · 2013Review
- Minocycline alleviates beta-amyloid protein and tau pathology via restraining neuroinflammation induced by diabetic metabolic disorder.Clinical interventions in aging · 2013Article
- Minocycline blocks lipopolysaccharide induced hyperalgesia by suppression of microglia but not astrocytes.Neuroscience · 2012Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 1 institution in 1 country.
Funding
Abstract
Human immunodeficiency virus type 1 (HIV-1) infection of the brain produces a characteristic disease called acquired immunodeficiency syndrome (AIDS) dementia in which productive infection and inflammatory activation of microglia and macrophages play a central role. In this report, the authors demonstrate that minocycline (MC), a second-generation tetracycline with proven safety and penetration to the central nervous system, potently inhibited viral production from microglia. Inhibition of viral release was sustained through the entire course of infection and even when the drug exposure was limited to the first day of infection. Minocycline was effective even at low viral doses, and against R5- and X4R5-HIV, as well as in single-cycle reporter virus assays. Electrophoretic mobility shift analysis showed that minocycline inhibited nuclear factor (NF)-kappaB activation in microglia. HIV-1 long terminal repeat (LTR)-promoter activity in U38 cells was also inhibited. These results, combined with recently demonstrated in vivo anti-inflammatory effects of MC on microglia, suggest a potential utility for MC as an effective adjunct therapy for AIDS dementia.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.